Health Care Leads Sectors as Drugmakers Post Earnings Beats

Health Care recorded the clear weekly lead among the eleven Select Sector SPDR funds. Its primary vehicle, the exchange-traded fund Health Care Select Sector SPDR Fund (XLV), posted +3.1% on the week, outpacing the S&P 500 at -0.6%. Across the broader market, 9 of the 11 sector funds rose this week. Inside the sector, breadth was positive, with 55.9% of its member companies advancing on the week. The group's performance was led by Regeneron Pharmaceuticals Inc at +15.3%, which reported third-quarter revenue and earnings growth. The sector was further propelled as Eli Lilly lifted its full-year revenue outlook by $5.5 billion and raised profit targets.

Other large-cap holdings reinforced the sector's momentum. Merck supported the advance after it posted 5% quarterly sales growth, increased its full-year guidance, and announced positive clinical milestones across its oncology pipeline. In medical technology, GE HealthCare also helped lift the fund after it topped quarterly revenue and profit expectations. These earnings beats provided a solid fundamental foundation for the group, reinforcing confidence in the sector's operational stability.

Behind the headline numbers, company-level returns showed wide divergence. In addition to revenue and earnings growth, Regeneron benefited from an expanded alliance with Sanofi and regulatory approval for Pasatru. At the opposite end of the fund, Illumina Inc sat at the bottom of the sector, finishing the week at -12.4%. The genomic tools maker dropped after it reported third-quarter revenue of $1.13 billion. The company also disclosed that its rest-of-world growth metric excludes Greater China following its inclusion on China's Unreliable Entities List.

The contrast between large-cap winners and smaller constituents explains the fund's overall advance. While XLV posted +3.1%, an equal-weighted measure across member stocks came in at +0.6%. The gap between the cap-weighted fund and the equal-weighted baseline demonstrates that mega-cap pharmaceutical names drove the bulk of the gains. Sector breadth stood at 55.9%, indicating that while more than half of the group advanced, participation was far from uniform. The advance reflected targeted demand for cash-generative drugmakers rather than a universal lift across all health care sub-industries.

This week's solid performance extends a positive run for the sector. Over the trailing month, XLV is +9.8%, and across the trailing three months the fund stands at +13.7%. Yet context matters more than short-term leadership. One solid week rarely changes what a sector is, and this week did not alter the fundamental reality of Health Care. The sector remains a defensive, mature group defined by patent cliffs, regulatory oversight, and clinical development risks. While earnings surprises can deliver clear weekly gains, they do not turn the sector into a high-growth vehicle.